Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Anxiety

    Current Location

    Search
    Anxiety
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      172 Anxiety Trials Near You

      Power is an online platform that helps thousands of Anxiety patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      CYB003 for Depression

      Columbus, Ohio
      The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2
      Age:21 - 65

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Substance Use, Others
      Must Be Taking:Antidepressants

      40 Participants Needed

      ABBV-932 for Generalized Anxiety Disorder

      Columbus, Ohio
      Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
      Stay on current meds

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Major Depression, Others
      Must Be Taking:Antidepressants

      315 Participants Needed

      Focused Ultrasound Thalamotomy for Epilepsy and Anxiety

      Columbus, Ohio
      The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain. For this study, the targeted area of the brain is the anterior nucleus of the thalamus. This brain region may cause seizures and may also be involved in anxiety. The study will test if FUSA is safe and tolerated, and if it reduces anxiety and brain response to threat in patients with anxiety receiving the procedure for partial-onset epilepsy that is resistant to medications.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Low Seizure Frequency, Generalized Epilepsy, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets

      10 Participants Needed

      IMPROVE for Binge Drinking and Anxiety

      Columbus, Ohio
      Nearly 60% of college students use alcohol and 30% binge drink monthly. This is alarming given that heavy alcohol use is linked to serious detrimental outcomes. Despite various prevention and intervention strategies, heavy alcohol use has remained relatively stable over the past decade. Individual differences in stress response connote risk for alcohol use disorder. Anxiety sensitivity (AS) and intolerance of uncertainty (IU) are two key cognitive vulnerabilities that can hinder resilience by amplifying stress responses and promoting maladaptive coping strategies, such as alcohol use. Effective stress management is a cornerstone of resilience. The Intervention for Managing Psychological Responding to Overwhelming Emotions (IMPROVE) targets AS and IU, key barriers to resilience, by modifying cognitive processes that amplify stress and negative affect. In this study, undergraduate students who engage in heavy drinking behaviors and experience elevated anxiety symptoms will be randomized to IMPROVE or a control health promotion intervention (N=20 per arm). All participants will complete daily ecological momentary assessments (EMA) delivered to participants' mobile phones to capture real-world alcohol use before, during, and after the intervention. The investigators will evaluate the feasibility and acceptability of IMPROVE (Aim 1). The investigators will also include a multimodal battery of self-report and objective lab-based measures of AS and IU involving startle eyeblink potentiation and event-related potentials via electromyography (EMG) and electroencephalography (EEG). This will allow the investigators to examine whether IMPROVE changes IU and AS, and to assess if changes in these targets are associated with changes in alcohol use (Aim 2).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Substance Use Disorder, Others

      40 Participants Needed

      MOMI PODS for Postpartum Health

      Columbus, Ohio
      The investigator's long-term goal is to mitigate pregnancy-related mortality (PRM) risk by systematically delivering integrated clinical and supportive care that is effective, equitable, and scalable. The investigator's central hypothesis is that the Multi-modal Maternal Infant Perinatal Outpatient Delivery System (MOMI PODS) will mitigate postpartum (PP) risk and reduce disparities in PP risk by improving biopsychosocial profiles and facilitating access to evidence-based clinical and supportive care. To test this hypothesis, the investigators will conduct a hybrid type 1 randomized controlled trial (RCT) of MOMI PODS versus enhanced usual care (EUC, which we will term MOMI CARE) among a total sample of 384 mother-infant dyads (192/group) following pregnancy affected by a cardiometabolic and/or mental health condition. The investigators will enroll participants on PP day 1 and collect data at baseline and 6 months and 1 year PP. The investigators will collect implementation and service data across sites.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Seizure Disorder, Major Infant Complications, Others

      384 Participants Needed

      New Therapy for Anxiety and Substance Use Disorder

      Columbus, Ohio
      The clinical trial aims to conduct a feasibility, acceptability, and usability clinical trial of a modular CBT-based and technologically enhanced intervention for people with an SUD and recently enrolled in IOP, probe target engagement and change in clinical outcomes, and examine attrition rates in IOP. This study will enroll 40 adults who are currently enrolled in IOP, have a substance use disorder, and experience elevated anxiety. 20 individuals will be randomized to the experimental intervention, "Intervention for Managing Physical Reactions to Overwhelming Emotions" (IMPROVE), and 20 individuals will be randomized to the active control group, "Physical Health Education Treatment" (PHET). Participants will be asked to complete a baseline assessment of mood, substance use, and psychophysiology. Participants will then completed ecological momentary assessments (EMA) via smartphone technology 4 times a day for \~ 28 days (the day following the baseline assessment until the 3rd intervention session). Participants will complete one 45 minute - 1 hour intervention each week for 3 weeks (either the IMPROVE or PHET intervention, pending randomization). Following the last intervention session, participants will return to the lab to complete a post-intervention assessment that mirrors the baseline assessment and then complete follow-up surveys 1- and 3-months post intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Cognitive Impairment, Psychosis, Others

      40 Participants Needed

      Virtual Reality Game for Procedural Pain and Anxiety

      Columbus, Ohio
      This study will assess the feasibility and efficacy of our Virtual Reality Pain Alleviation Therapy (VR-PAT) for pain management during pediatric and young adult outpatient laser procedures and evaluate the impact of VR use on reducing anxiety in patients undergoing dermatologic laser procedures. The investigators hypothesize that patients using VR-PAT will report less pain and anxiety during the laser procedure than patients who do not play the game.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:5 - 25

      Key Eligibility Criteria

      Disqualifiers:Vision, Hearing, Cognitive Impairments, Others

      40 Participants Needed

      Little NIRVANA for Procedural Anxiety

      Columbus, Ohio
      The aim of this study is to test the feasibility of using Little NIRVANA (augmented reality (AR)) for managing anxiety and pain for children 2-8 years old during hospital emergency peripheral intravenous (PIV) insertions. The investigators hypothesize that Little NIRVANA plus a numbing cream will reduce pain and anxiety for patients undergoing PIV placement in the emergency department (ED) when compared to the cream alone. It is anticipated that using the Little NIRVANA will not increase the ED length of stay, failed PIV placement attempts, or the need for additional intervention.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:2 - 8

      Key Eligibility Criteria

      Disqualifiers:Non-English Speaking, Critical Illness

      130 Participants Needed

      Computerized Anxiety Treatment for Mild Alzheimer's Disease

      Columbus, Ohio
      The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are: 1. Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD 2. Efficacy of CAST in reducing care partner burden among care partners of people living with MCI/mild ADRD 3. Explore treatment mechanisms using a multi-modal assessment battery of anxiety sensitivity and anxiety Participants will complete six in-person visits including a baseline assessment, two intervention sessions, and three follow-up assessments at 1, 3, and 6-months posttreatment. Participants will also complete three weeks of ecological momentary assessments (EMAs) for one week prior to intervention, one week between intervention sessions, and one week after intervention. If there is a comparison group: Researchers will compare CAST to HEC to see if CAST reduces anxiety and related symptoms in older adults with MCI/mild ADRD and care partner burden to a greater degree than HEC.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Severe Mental Illness, Others

      388 Participants Needed

      Healthy Lifestyle Intervention for Emotional Distress During Pregnancy

      Columbus, Ohio
      This trial tests a program that helps pregnant minority women manage their thoughts and emotions to reduce stress. It aims to improve mental health and birth outcomes for Black and Hispanic women who are emotionally distressed.
      No Placebo Group

      Trial Details

      Trial Status:Completed
      Age:18 - 40
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      299 Participants Needed

      RE104 for Adjustment Disorder

      Columbus, Ohio
      The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Psychotic, Others
      Must Be Taking:Antidepressants

      100 Participants Needed

      mHealth Intervention for Cancer

      Columbus, Ohio
      In response to the symptom needs experienced in advanced cancer, the investigators developed a brief, integrated CBT-ACT symptom management intervention, Finding Our Center Under Stress (FOCUS). Using FOCUS, participants learn skills to self-manage sleep, worry-anxiety, depression, and fatigue and improve their ability to focus on what matters most to them despite these symptoms. Results of the pilot randomized controlled trial with people with advanced cancer demonstrate improved sleep on both self-report and physiologic (i.e., actigraphy) measures, and improvements on worry, depression, and fatigue interference with strong effect sizes ranging from d= 0.59 to 0.98 and sleep effects 12 months post-treatment. The investigators refined the fatigue module with exercise modifications and beta-tested the FOCUS intervention as an mHealth web-based app for acceptability with 10 diverse patients with advanced cancer -100% would recommend for other advanced cancer patients. The overall objective of this proposed randomized effectiveness trial is to evaluate the impact of this telemedicine-mHealth symptom cluster intervention with patients from rural and Appalachian communities (where the PI was raised). Innovative features include a focus on a symptom cluster including anxiety, integrated CBT-ACT intervention, telemedicine-mHealth delivery method, and biobehavioral approach evaluating behavioral and inflammatory mediators.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Night-shift Work, Untreated Bipolar, Substance Abuse, Others

      120 Participants Needed

      Cognitive Behavioral Therapy for Anxiety Prevention in Servicemembers

      Columbus, Ohio
      The goal of this clinical trial is to test whether inclusion of cognitive behavioral therapy (CBT) for Uncertainty-Enhanced (CUE) with Lethal Means Counseling (LMC) is acceptable, feasible, and efficacious in addressing secure firearm storage and associated psychological constructs in active duty servicemembers. The clinical trial aims to: * Assess the preliminary efficacy of a LMC intervention, augmented with CUE, on firearm storage practices * Examine mechanisms through which CUE and LMC increase firearm storage practices * Assess credibility and acceptability of LMC Participants will complete: * One baseline visit * Two intervention sessions-CUE and LMC * Six brief surveys per day for 28 days using a mobile application * One mid-point survey and five follow-up surveys
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Cognitive Impairment, Psychosis, Mania, Others

      100 Participants Needed

      Stress Management and Resilience Training for Stress in Air Force Personnel

      Dayton, Ohio
      This trial examines the effectiveness of the SMART program in helping U.S. Air Force personnel manage stress and build resilience. The program includes practices like gratitude and mindfulness and can be delivered in-person, via video calls, or through computer-based training. The study aims to find out which delivery method is most effective. The SMART program has been previously tested in various settings, including healthcare workers and employees at a medical center, showing significant improvements in stress, resilience, and mindfulness.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-active Personnel, BMTs, Prisoners, Others

      500 Participants Needed

      Escitalopram for Anxiety

      Cincinnati, Ohio
      This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Mood Disorders, Intellectual Disability, Trauma, Others
      Must Not Be Taking:SSRIs, Psychiatric Medications

      132 Participants Needed

      Duloxetine vs Escitalopram for Depression

      Cincinnati, Ohio
      Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Suicide Risk, Others
      Must Not Be Taking:Antidepressants

      60 Participants Needed

      Fasedienol Nasal Spray for Social Anxiety Disorder

      Cincinnati, Ohio
      This Phase 3 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement. In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      236 Participants Needed

      Sertraline for Anxiety Disorders

      Cincinnati, Ohio
      A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:8 - 17

      Key Eligibility Criteria

      Disqualifiers:Mood, Eating, Bipolar, Psychotic, Others
      Must Not Be Taking:SSRIs, CNS Drugs

      150 Participants Needed

      Combination Therapy for Anxiety Disorders

      Cincinnati, Ohio
      Pediatric onset anxiety disorders (generalized anxiety, social anxiety, separation anxiety) are highly prevalent, and if untreated, are impairing into adolescence and adulthood. In the largest comparative efficacy study remission occurred in about 65% of children and adolescents treated with a combination of a selective serotonin reuptake inhibitors (SSRI) and cognitive behavioral therapy (CBT). In contrast, CBT without an SSRI achieved remission in 35% of children at 3 months and 45% at 6 months-a 30% and 20% difference, respectively. Despite the difference in remission rates, CBT alone is the preferred treatment of most patients and families. Lack of awareness of the significant difference in remission rates and concerns about medication side effects may drive patient and family preference even though SSRIs have a positive safety profile. Critiques of CBT in the above study suggest that CBT was not as effective as it could be due to short treatment duration, restricted family involvement and limited exposure sessions. Would the combination of CBT and an SSRI still be superior to CBT only, if CBT was of longer duration, and included more family involvement and exposure sessions? In the Partners in Care for Anxious Youth (PCAY) study, children and adolescents with an anxiety disorder ages 7-17 years followed in pediatric primary care clinics affiliated with three institution: Lurie Children's Hospital of Chicago, University of California Los Angeles and University of Cincinnati will be randomized to one of two treatment arms; either CBT only or CBT combined with an SSRI (either fluoxetine, sertraline, or escitalopram). CBT in PCAY will be 6 months in duration and include more family involvement, and more exposure opportunities than past trials. The 6-month acute treatment phase will be followed by 6 months of followup. The primary outcome will be anxiety symptom remission and reduction in impairment over 6 and 12-months.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:7 - 17

      Key Eligibility Criteria

      Disqualifiers:Autism, Bipolar, Schizophrenia, Others
      Must Not Be Taking:Fluoxetine, Sertraline, Citalopram, Others

      468 Participants Needed

      Antidepressants for Anxious Depression

      Cincinnati, Ohio
      Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Suicide Risk, Alcohol Use, Others
      Must Be Taking:Escitalopram, Duloxetine

      84 Participants Needed

      Why Other Patients Applied

      "I've tried a number of antidepressants over the years and nothing has made a significant difference. I have a family history of alcohol use and I am interested to try ketamine."

      YU
      Anxiety PatientAge: 62

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "Sertraline has only been somewhat helpful for managing my anxiety. I tried prescribed benzodiazepines in the past, but I didn't like the side effects (drowsiness, some memory loss). I'm hoping I'll benefit from this trial."

      AT
      Anxiety PatientAge: 34

      "I want to try a trial because I've been on numerous, numerous different drugs for my anxiety. It's been almost 4 years since I've been on any medications. But I've noticed a gradual and steady increase in my symptoms. I just want some relief and to start to see the good things that life has to offer."

      EQ
      Anxiety PatientAge: 55

      "I have been researching ketamine and I feel it would be a good fit. I'd like I try in a controlled environment. Plus I've been on the same drugs for years and I just feel stuck."

      DJ
      Anxiety PatientAge: 64
      Match to a Anxiety Trial

      Fasting for Type 1 Diabetes

      Cincinnati, Ohio
      Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      10 Participants Needed

      Psychological Intervention for Parents of Babies with Congenital Heart Defects

      Cincinnati, Ohio
      Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:DiGeorge Syndrome, Untreated Psychiatric, Others

      50 Participants Needed

      Power Preferred

      SEP-363856 for Generalized Anxiety Disorder

      North Canton, Ohio
      This Phase 2/3 clinical trial is designed to evaluate SEP-363856 for Generalized Anxiety Disorder
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Unstable Medical Condition, Others
      Must Not Be Taking:Antidepressants

      434 Participants Needed

      ITI-1284 for Generalized Anxiety Disorder

      North Canton, Ohio
      This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
      Stay on current meds

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Suicidal Risk, Others
      Must Be Taking:Paroxetine, Venlafaxine XR, Duloxetine, Escitalopram, Buspirone

      705 Participants Needed

      Medical Cannabis for Chronic Pain

      Sandusky, Ohio
      This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:7+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Suicidality, Psychosis, Others

      200000 Participants Needed

      SPT-300 for Depression

      North Canton, Ohio
      This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Noncompliance, Pregnancy, Others

      360 Participants Needed

      SPT-300 for Depression

      North Canton, Ohio
      This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bipolar Disorder, Schizophrenia, OCD, Others
      Must Not Be Taking:Antidepressants

      360 Participants Needed

      Active on Power

      Fasedienol Nasal Spray for Social Anxiety Disorder

      Middleburg Heights, Ohio
      This Phase 2 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement. In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Alcohol Use, Others
      Must Not Be Taking:Psychotropics, CBD, Others

      60 Participants Needed

      Active on Power

      MM120-300 for Anxiety

      Cleveland, Ohio
      The reason for this study is to see if the investigational study drug, called MM120, can help people with Anxiety compared to a placebo. A placebo is an inactive drug that looks like MM120 but does not contain any active ingredients.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:PTSD, Schizophrenia, Bipolar, Others
      Must Not Be Taking:Psychedelics

      198 Participants Needed

      Arts Activities for Anxiety

      Cleveland, Ohio
      The Developing Resilience and Anxiety Management Through the Arts (DRAMA) Study examines the degree to which the arts can help to address stress, anxiety, and sad mood in children and adolescents. The researchers will pair theatrical improvisation exercises with cognitive-behavioral therapy (CBT) techniques versus improvisation exercises alone versus a social craft group on reducing elevated levels of anxiety and depression.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:8 - 17

      Key Eligibility Criteria

      Disqualifiers:Conduct Disorder, Autism, Psychosis, Eating Disorders, Others
      Must Not Be Taking:Psychotropics

      110 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Social Anxiety Clinical Trials

      Top Anxiety Disorder Clinical Trials

      Top Generatlized Anxiety Disorder Clinical Trials

      Top Social Anxiety Disorder Clinical Trials

      Top Hyperhidrosis Clinical Trials

      Top Amblyopia Clinical Trials

      Top Amyloidosis Clinical Trials

      Top Mrsa Clinical Trials

      Top Cholesterol Clinical Trials

      Top Cardiovascular Clinical Trials

      Top Asd Clinical Trials

      Top Eoe Clinical Trials

      By Trial

      Combination Therapy for Anxiety Disorders

      Self-Management Intervention for Anxiety in Respiratory Failure Survivors

      ABMT for Social Anxiety Disorder

      Online Psychotherapy for Anxiety and Depression in Cancer Patients

      Inflammation's Impact on Reward Response in Aging and Anxiety

      Sertraline + Cognitive Behavioural Therapy for Anxiety in Autism

      Virtual Reality Therapy for Anxiety

      CALM Intervention for Childhood Anxiety Disorder

      Being Brave + Parent Education for Childhood Anxiety Disorder

      Virtual Reality for Pediatric Dental Anxiety

      MAC Therapy for Anxiety in Cancer Patients

      Exercise Intensity for Anxiety

      Related Searches

      Top Prostate-cancer Clinical Trials near Anaheim, CA

      Top Prostate-cancer Clinical Trials near High Point, NC

      Top Schizophrenia Clinical Trials near Miami, FL

      Top Clinical Trials near Dakota Dunes, SD

      Saline Flush for Empyema

      Vagus Nerve Stimulation for Alzheimer's Disease

      Estradiol + Olaparib for Breast Cancer

      Mobile App for Child Development

      HMPL-306 for Isocitrate Dehydrogenase Deficiency

      Azacitidine + Venetoclax vs Stem Cell Transplant for Acute Myeloid Leukemia

      Varenicline + Nicotine Patch for Quitting Smoking

      Ketamine for Acute Pain

      Frequently Asked Questions

      How much do Anxiety clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Anxiety clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Anxiety trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Anxiety is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Anxiety medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Anxiety clinical trials?

      Most recently, we added SPG Block for Anxiety, Morphine or Ketamine for Pain and Spiritual Care for Well-being to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards recruiting for Anxiety trials?

      The Anxiety clinics currently recognized as Power Preferred are: Neuro-Behavioral Clinical Research, Inc. Site #115 in North Canton, Ohio

      What is the best fix for anxiety?

      There isn’t one magic “fix” for anxiety, but studies show that most people improve with either cognitive-behavioural therapy (CBT) and/or daily medication such as an SSRI or SNRI, chosen together with a qualified clinician. Adding regular exercise, mindfulness or breathing practice, good sleep and limiting caffeine or alcohol can boost results, so think of treatment as a toolbox—start with proven professional help (therapy and possibly medicine) and layer the healthy habits on top for longer-term control.

      What does 333 mean for anxiety?

      “333” is a fast grounding trick for sudden anxiety: look around and name three things you see, notice three sounds, then deliberately move three body parts (for example, roll your shoulders, wiggle your toes, stretch your fingers). Focusing on simple sights, sounds, and movements pulls your attention out of racing thoughts and signals your nervous system that you’re safe, which can ease the physical surge of anxiety for a few moments. Use it as a quick reset; if anxiety keeps returning or interferes with daily life, add longer-term strategies like CBT, exercise, or speaking with a healthcare professional.

      Do anxiety bracelets really work?

      Bracelets made of magnets, copper, crystals, or “negative ions” have not been proven to calm anxiety, but a band can still help if you use it as a cue to do something that does work—e.g., press an acupressure point, follow a paced-breathing vibration, or ground yourself with a quick mindfulness check (small studies of these techniques show temporary relief). In other words, the bracelet is a prompt, not the treatment; for lasting improvement pair that prompt with evidence-based care such as cognitive-behavioral therapy, relaxation training, or medication discussed with a healthcare professional.

      Does gabapentin treat anxiety?

      Gabapentin isn’t FDA-approved for any anxiety disorder, but doctors sometimes prescribe it “off-label” when standard options (talk therapy, SSRIs/SNRIs, or—short term—benzodiazepines) haven’t worked or can’t be used. Small studies suggest it can ease social or short-term situational anxiety at doses of about 900–2,400 mg a day, yet the evidence is modest and it can cause sleepiness, dizziness, and withdrawal if stopped abruptly. If you’re considering it, discuss with your clinician how its uncertain benefits, side-effects, and need for slow tapering stack up against better-studied treatments and non-drug approaches like cognitive-behavioral therapy.

      What is the FDA approved device for anxiety?

      Strictly speaking, the FDA has not “approved” any device just for anxiety; rather, it has cleared several prescription-only cranial electrotherapy stimulators (CES) through its 510-k process—including Alpha-Stim AID, Fisher-Wallace Stimulator, and Cervella—for short-term relief of anxiety (often along with insomnia or depression). These devices send a very mild electrical current through clips on the earlobes for about 20–60 minutes a day over several weeks, and their use should be discussed with a healthcare professional to be sure they’re safe and appropriate for you.

      What drug is used in rapid relief of anxiety?

      For symptoms that need relief within minutes to an hour, doctors usually prescribe a short-acting benzodiazepine such as lorazepam or alprazolam; these calm the nervous system quickly but can cause drowsiness and, with repeated use, dependence, so they are meant for short-term or “as-needed” use. Other fast options include the antihistamine hydroxyzine (works in ~30 min) or propranolol for one-time performance anxiety, while longer-term control is handled with medicines like SSRIs and therapy.

      What are the 4 R's of anxiety?

      Professionals usually mean one of two quick, four-step loops: 1) Recognize the anxious thought or body cue, Reassure yourself with realistic facts, Relax with slow breathing, then Refocus on your task; or 2) Relabel the thought as “just anxiety,” Re-attribute it to a misfiring alarm, Refocus on a chosen activity for a few minutes, and Re-value the thought as unimportant noise. Some wellness articles cite Rest, Relaxation, Replenish, Release, but that version is a general self-care checklist, not an in-the-moment anxiety technique.

      What is intense therapy for anxiety?

      “Intensive” therapy for anxiety is the same proven treatments (like CBT and exposure exercises) delivered in a much bigger dose—several hours a day for a short stretch—through formats such as weekend “boot-camps,” 3–5-day-a-week intensive outpatient programs, or brief residential stays. This immersive approach is used when anxiety is severe, hasn’t improved with weekly sessions, or rapid progress is needed, and studies show it can match or outperform standard once-a-week therapy. To explore it, ask your provider or insurer about clinics that offer “intensive CBT/ERP,” “IOP,” or “PHP” programs run by licensed anxiety specialists.

      Can I live a long life with anxiety?

      Yes. Large studies show that untreated, severe anxiety can slightly raise the risk of early death—mainly by increasing suicide risk and unhealthy behaviors—but the effect is small and is greatly reduced when the condition is recognized and treated. People who get evidence-based care (therapy, possible medication), stay active, avoid smoking/drugs, and keep regular medical check-ups typically live just as long as those without anxiety, so focusing on treatment and healthy routines is the key to a long life.

      What is the 5 4 3 2 1 anxiety trick?

      The 5-4-3-2-1 “grounding” trick is a rapid way to pull your mind out of racing thoughts: name five things you can see, four you can touch, three you hear, two you smell, and one you can taste, taking slow breaths as you go. Engaging each sense crowds out worry signals and anchors you in the present; repeat or shorten the list any time a panic spike or rumination hits. It’s a quick coping tool—helpful in the moment—but if anxiety is frequent or disabling, pair it with ongoing care from a mental-health professional.